Influenza virosomes as an efficient system for adjuvanted vaccine delivery

Expert Opinion on Biological Therapy

Volumn 4, Issue 7, 2004, Pages 1139-1145

  Glück, Reinhard ^a   Moser, Christian ^a   Metcalfe, Ian C ^a  

^a Berna Biotech AG   (Switzerland)

Author keywords

Adjuvant; Delivery system; Influenza; Vaccine; Virosomes

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; DIPHTHERIA TOXOID; HEPATITIS A ANTIGEN; HEPATITIS A VACCINE; INACTIVATED VACCINE; INFLUENZA VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TETANUS TOXOID; TUMOR ANTIGEN; VIROSOME; VIRUS ANTIGEN;

DRUG DELIVERY SYSTEM; ELECTRON MICROSCOPY; HUMAN; INFLUENZA; INFLUENZA VIRUS; MEMBRANE FUSION; NONHUMAN; REVIEW; VACCINE PRODUCTION;

ADJUVANTS, IMMUNOLOGIC; ANTINEOPLASTIC AGENTS; CANCER VACCINES; EPITOPES; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HEPATITIS A VACCINES; HEPATITIS A VIRUS; HUMANS; INFLUENZA VACCINES; MALARIA VACCINES; MEMBRANE FUSION; MOLECULAR MIMICRY; NEOPLASMS; OLIGONUCLEOTIDES, ANTISENSE; ORTHOMYXOVIRIDAE; THIONUCLEOTIDES; VACCINES, VIROSOME; VIROSOMES;

INFLUENZA VIRUS;

EID: 3142657967     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.4.7.1139     Document Type: Review

References (62)

1. SCHIJNS VE: Immunological concepts of vaccine adjuvant activity. Curr. Opin. Immunol. (2000) 12(4):456-463.
2. O'HAGAN DT, MACKICHAN ML SINGH M: Recent developments in adjuvants for vaccines against infectious diseases. Biomol. Eng. (2001) 18(3):69-85.
3. MOSER C, METCALFE IC, VIRET JF: Virosomal adjuvanted antigen delivery systems. Expert Rev. Vaccines (2003) 2(2):189-196.
4. BUNGENER L, IDEMA J, TER VEER W, HUCKRIEDE A, DAEMEN T, WILSCHUT J: Virosomes in vaccine development: induction of cytotoxic T lymphocyte activity with virosome-encapsulated protein antigens. J. Liposome Res. (2002) 12(1-2):155-163. A paper discussing the potential for virosomes to elicit a class I MHC CTL response.
5. HUCKRIEDE A, BUNGENER L, TER VEER W et al.: Influenza virosomes: combining optimal presentation of hemagglutinin with immunopotentiating activity. Vaccine (2003) 21(9-10):925-931.
6. ZURBRIGGEN R: Immunostimulating reconstituted influenza virosomes. Vaccine (2003) 21(9-10):921-924.
7. GLUCK R, METCALFE IC: New technology platforms in the development of vaccines for the future. Vaccine (2002) 20(Suppl. 5):B10-B16.
8. BUNGENER L, HUCKRIEDE A, WILSCHUT J, DAEMEN T: Delivery of protein antigens to the immune system by fusion-active virosomes: a comparison with liposomes and ISCOMs. Biosci. Rep. (2002) 22(2):323-338.
9. BUNGENER L, SERRE K, BIJL L et al.: Virosome-mediated delivery of protein antigens to dendritic cells. Vaccine (2002) 20(17-18):2287-2295.
10. MISCHLER R, METCALFE IC: Inflexal V a trivalent virosome subunit influenza vaccine: production. Vaccine (2002) 20(Suppl. 5):B17-B23. A detailed description of influenza virosome production and quality control for the production of the virosome influenza vaccine, Inflexal V.
11. ZURBRIGGEN R, NOVAK-HOFER I, SEELIG A, GLUCK R: IRIV-adjuvanted hepatitis A vaccine: in vivo absorption and biophysical characterization. Prog. Lipid Res. (2000) 39(1):3-18.
12. POLTL-FRANK F, ZURBRIGGEN R, HELG A et al.: Use of reconstituted influenza virus virosomes as an immunopotentiating delivery system for a peptide-based vaccine. Clin. Exp. Immunol. (1999) 117(3):496-503.
13. SCHIJNS VE: Immunological concepts of vaccine adjuvant activity. Curr. Opin. Immunol. (2000) 12(4):456-463.
14. TEW JG, PHIPPS RP, MANDEL TE: The maintenance and regulation of the humoral immune response: persisting antigen and the role of follicular antigen-binding dendritic cells as accessory cells. Immunol. Rev. (1980) 53:175-201.
15. CAUX C, LIU YJ, BANCHEREAU J: Recent advances in the study of dendritic cells and follicular dendritic cells. Immunol. Today (1995) 16(1):2-4.
16. GLUCK R, MISCHLER R, BRANTSCHEN S et al.: Immunopotentiating reconstituted influenza virus virosome vaccine delivery system for immunization against hepatitis A. J. Clin. Invest. (1992) 90(6):2491-2495.
17. ZURBRIGGEN R, GLUCK R: Immunogenicity of IRIV-versus alum-adjuvanted diphtheria and tetanus toxoid vaccines in influenza primed mice. Vaccine (1999) 17(11-12):1301-1305.
18. CUSI MG, ZURBRIGGEN R, CORREALE P et al.: Influenza virosomes are an efficient delivery system for respiratory syncytial virus-F antigen inducing humoral and cell-mediated immunity. Vaccine (2002) 20(29-30):3436-3442.
19. WILSON IA, SKEHEL JJ, WILEY DC: Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 A resolution. Nature (1981) 289(5796):366-373.
20. SKEHEL JJ, WILEY DC: Coiled coils in both intracellular vesicle and viral membrane fusion. Cell (1998) 95(7):871-874.
21. BULLOUGH PA, HUGHSON FM, SKEHEL JJ, WILEY DC: Structure of influenza haemagglutinin at the pH of membrane fusion. Nature (1994) 371(6492):37-43.
22. HERNANDEZ LD, HOFFMAN LR, WOLFSBERG TG, WHITE JM: Virus-cell and cell-cell fusion. Ann. Rev. Cell Dev. Biol. (1996) 12:627-661.
23. SKEHEL JJ, WILEY DC: Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Ann. Rev. Biochem. (2000) 69:531-569.
24. DURRER P, GALLI C, HOENKE S et al.: H+-induced membrane insertion of influenza virus hemagglutinin involves the HA2 amino-terminal fusion peptide but not the coiled coil region. J. Biol. Chem. (1996) 271:13417-13421.
25. HAN X, BUSHWELLER JH, CAFISO DS, TAMM LK: Membrane structure and fusion-triggering conformational change of the fusion domain from influenza haemagglutinin. Nat. Struct. Biol. (2001) 8:715-720.
26. SCHOEN P, LESERMAN L, WILSCHUT J: Fusion of reconstituted influenza virus envelopes with liposomes mediated by streptavidin/biotin interactions. FEBS Lett. (1996) 390(3):315-318.
27. GUNTHER-AUSBORN S, SCHOEN P, BARTOLDUS I, WILSCHUT J, STEGMANN T: Role of hemagglutinin surface density in the initial stages of influenza virus fusion: lack of evidence for cooperativity. J. Virol. (2000) 74(6):2714-2720.
28. TAKEDA M, LESER GP, RUSELL CJ, LAMB RA: Influenza virus hemagglutinin concentrates in lipid raft microdomains for efficient viral fusion. Proc. Natl. Acad. Sci. USA (2003) 100(25):14610-14617.
29. BENTZ J, MITTAL A: Architecture of the influenza hemagglutinin membrane fusion site. Biochim. Biophys. Acta (2003) 1614(1):24-35.
30. MITTAL A, BENTZ J: Comprehensive kinetic analysis of influenza hemagglutinin-mediated membrane fusion: role of sialate binding. Biophys. J. (2001) 81(3):1521-1535.
31. HERNANDEZ LD, HOFFMAN LR, WOLFSBERG TG, WHITE JM: Virus-cell and cell-cell fusion. Ann. Rev. Cell Dev. Biol. (1996) 12:627-661.
32. PARK HE, GRUENKE JA, WAITE JM: Leash in the groove mechanism of membrane fusion. Nat. Struct. Biol. (2003) 10(12):1048-1053.
33. HUANG Q, SIVARAMAKRISHNA RP, LUDWIG K, KORTE T, BOTTCHER C, HERRMANN A: Early steps of the conformational change of influenza virus hemagglutinin to a fusion active state: stability and energetics of the hemagglutinin. Biochim. Biophys. Acta (2003) 1614(1):3-13.
34. MADHUSOODANAN M, LAZARIDIS T: Investigation of pathways for the low-pH conformational transition in influenza hemagglutinin. Biophys. J. (2003) 84(3):1926-1939.
35. WEBER T, PAESOLD G, GALLI C, MISCHLER R, SEMENZA G, BRUNNER J: Evidence for H(+)-induced insertion of influenza hemagglutinin HA2 N-terminal segment into viral membrane. J. Biol. Chem. (1994) 269:18353-18358.
36. ZAMBON MC: The pathogenesis of influenza in humans. Rev. Med. Virol. (2001) 11(4):227-241. An excellent review of influenza viruses and their pathogenicity.
37. ARKEMA A, HUCKRIEDE A, SCHOEN P, WILSCHUT J, DAEMEN T: Induction of cytotoxic T lymphocyte activity by fusion-active peptide-containing virosomes. Vaccine (2000) 18(14):1327-1333.
38. ROTT O, CHARREIRE J, MIGNON-GODEFROY K, CASH E: B cell superstimulatory influenza virus activates peritoneal B cells. J. Immunol. (1995) 155(1):134-142.
39. ROTT O, CHARREIRE J, SEMICHON M, BISMUTH G, CASH E: B cell superstimulatory influenza virus (H2-subtype) induces B cell proliferation by a PKC-activating, Ca(2+)-independent mechanism. J. Immunol. (1995) 154(5):2092-2103.
40. FEHR T, BACHMANN MF, BUCHER E et al.: Role of repetitive antigen patterns for induction of antibodies against antibodies. J. Exp. Med. (1997) 185(10):1721-1723.
41. BACHMANN MF, HENGARTNER H, ZINKERNAGEL RM: T helper cell-independent neutralizing B cell response against vesicular stomatitis virus: role of antigen patterns in B cell induction? Eur. J. Immunol. (1995) 25(12):3445-3451.
42. NOAD R, ROY P: Virus-like particles as immunogens. Trends Microbiol. (2003) 11(9):438-444.
43. MENGIARDI B, BERGER R, JUST M, GLUCK R: Virosomes as carriers for combined vaccines. Vaccine (1995) 13(14):1306-1315.
44. GLÜCK R, CRYZ S JR: IRIV Vaccine Delivery. In: New Generation Vaccines. Levine MM, Woodrow GC, Kaper JB, Cobon GS (Eds), Marcel Dekker, Inc., New York, USA (1997):247-252.
45. WIEDERMANN G, KUNDI M, AMBROSCH F: Estimated persistence of anti-HAV antibodies after single dose and booster hepatitis A vaccination (0-6 schedule). Acta Trop. (1998) 69(2):121-125.
46. HOLZER BR, HATZ C, SCHMIDT-SISSOLAK D, GLÜCK R, ALTHAUS B, EGGER M: Immunogenicity and adverse effects of inactivated virosome versus alum-adsorbed hepatitis A vaccine: a randomised controlled trial. Vaccine (1996) 14(10):982-986.
47. GLÜCK R, MISCHLER R, FINKEL B, QUE JU, SCARPA B, CRYZ SJ JR: Immunogenicity of new virosome influenza vaccine in elderly people. Lancet (1994) 344(8916):160-163.
48. CONNE P, GAUTHEY L, VERNET P, et al.: Immunogenicity of trivalent subunit versus virosome-formulated influenza vaccines in geriatric patients. Vaccine (1997) 15:1675-1679.
49. KANRA G, MARCHISIO P, FEITERNA-SPERLING C et al.: Comparison of immunogenicity and tolerability of a virosome-adjuvanted and a split influenza vaccine in children. Pediatr. Infect. Dis. J. (2004) 23(4):300-306.
50. CRYZ SJ, QUE JU, GLUCK R: A virosome vaccine antigen delivery system does not stimulate an antiphospholipid antibody response in humans. Vaccine (1996) 14(14):1381-1383.
51. WAELTI ER, GLUCK R: Delivery to cancer cells of antisense L-myc oligonucleotides incorporated in fusogenic, cationic-lipid-reconstituted influenza-virus envelopes (cationic virosomes). Int. J. Cancer (1998) 77(5):728-733.
52. CORREALE P, CUSI MG, SABATINO M et al.: Tumour-associated antigen (TAA)-specific cytotoxic T cell (CTL) response in vitro and in a mouse model, induced by TAA-plasmids delivered by influenza virosomes. Eur. J. Cancer (2001) 37(16):2097-2103.
53. LUYKX-DE BAKKER SA, DE GRUIJL TD, SCHEPER RJ, WAGSTAFF J, PINEDO HM: Dendritic cells: a novel therapeutic modality. Ann. Oncol. (1999) 10(1):21-27.
54. MASTROBATTISTA E, SCHOEN P, WILSCHUT J, CROMMELIN DJ, STORM G: Targeting influenza virosomes to ovarian carcinoma cells. FEBS Lett. (2001) 509(1):71-76.
55. WAELTI E, WEGMANN N, SCHWANINGER R et al.: Targeting her-2/neu with antirat Neu virosomes for cancer therapy. Cancer Res. (2002) 62(2):437-444. Targeted delivery of cytotoxic drugs via anti-rat Neu virosomes.
56. TSUJI M, RODRIGUES EG, NUSSENZWEIG S: Progress toward a malaria vaccine: efficient induction of protective anti-malaria immunity. Biol. Chem. (2001) 382(4):553-570.
57. CIBA FOUNDATION SYMPOSIUM: Synthetic Peptides as Antigens. Porter R, Whelan J (Eds), Wiley, Chichester, UK (1986).
58. MORENO R, JIANG L, MOEHLE K et al.: Exploiting conformationally constrained peptidomimetics and an efficient human-compatible delivery system in synthetic vaccine design. Chembiochem. (2001) 2(11):838-843. [Erratum in: Chembiochem. (2002) 3(4):270.]
59. MORENO R, JIANG L, MOEHLE K et al.: Exploiting conformationally constrained peptidomimetics and an efficient human-compatible delivery system in synthetic vaccine design. Chembiochem. (2001) 2(11):838-843. [Erratum in: Chembiochem. (2002) 3(4):270.]
60. PFEIFFER B, PEDUZZI E, MOEHLE K et al.: A virosome-mimotope approach to synthetic vaccine design and optimization: synthesis, conformation, and immune recognition of a potential malaria-vaccine candidate. Angew Chem. Int. Ed. Engl. (2003) 42(21):2368-2371.
61. MUELLER MS, RENARD A, BOATO F et al.: Induction of parasite growth-inhibitory antibodies by a virosomal formulation of a peptidomimetic of loop I from domain III of Plasmodium falciparum apical membrane antigen 1. Infect. Immun. (2003) 71(8):4749-4758.
62. HERRINGTON DA, CLYDE DF, LOSONSKY G et al.: Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites. Nature (1987) 328(6127):257-279.